Table 3.
Univariate log-rank analysis of the overall survival (OS) for the whole series.
| Characteristics | Number of patients | 1-year OS (%) | 5-year OS (%) | 10-year OS (%) | p-value by the log-rank test |
|---|---|---|---|---|---|
| Delay of diagnosis | |||||
| Metachronous | 24 (60.0%) | 66.2% | 55.1% | 55.1% | .220 |
| Synchronous | 16 (40.0%) | 91.7% | 80.2% | 80.2% | |
| Pathologic fracture | |||||
| Yes | 29 (72.5%) | 78.0% | 60.6% | – | .480 |
| No | 11 (27.5%) | 72.7% | 66.1% | 66.1% | |
| RAI Therapy | |||||
| Yes | 29 (72.5%) | 85.4% | 74.7% | 74.7% | .045 |
| No | 11 (27.5%) | 54.5% | 27.3% | – | |
| Radiotherapy | |||||
| Yes | 24 (60.0%) | 56.3% | 49.2% | 49.2% | .021 |
| No | 16 (40.0%) | 90.5% | 74.3% | 74.3% | |
| Tumor size | |||||
| <100 mm | 33 (82.5%) | 81.5% | 70.7% | 70.7% | .093 |
| >100 mm | 7 (17.5%) | 42.9% | 21.4% | 21.4% | |
| Location | |||||
| Pelvic ring | 12 (30.0%) | 91.7% | 59.4% | 59.4% | .542 |
| Other locations | 28 (70.0%) | 78.0% | 65.6% | 65.6% | |
| Histological Type | |||||
| Unknown | 11 (27.5%) | 72.7% | 72.7% | 72.7% | |
| Medullary | 2 (5.0%) | – | – | – | .440 |
| Papillary | 25 (62.5%) | 74.7% | 63.4% | 63.4% | |
| Vesicular | 2 (5.0%) | – | – | – | |
RAI, Radioactive Iodine therapy.